Turn Therapeutics Inc. (TTRX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted anti-inflammatory therapies, primarily focusing on its lead candidate GX-03 for atopic dermatitis (AD) and onychomycosis. The company completed a direct listing on Nasdaq in October 2025 and is classified as an Emerging Growth Company and Smaller Reporting Company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,820,865) | $(1,568,972) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.06) |
| Cash and Cash Equivalents (End of Period) | $10,288,510 | $3,189,943 |
| Working Capital (Excl. Derivative Liability) | ~$7.8 million | N/A |
| Long-Term Debt (Net) | $6,062,994 | $0 |
| Derivative Liability | $6,109,030 | $3,028,401 |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly to $6.8 million from $1.6 million year-over-year. This was driven primarily by a $2.6 million non-cash loss from the change in fair value of derivative liabilities and $1.1 million in amortization of deferred offering costs.
- Operating Expenses: Total operating expenses rose to $2.8 million from $1.8 million. Research and Development (R&D) expenses increased by $0.5 million due to the ongoing Phase 2 clinical trial for GX-03 in AD. General and Administrative (G&A) expenses increased by $0.6 million, largely due to higher stock-based compensation.
- Debt Financing: The company entered a new Loan and Security Agreement with Avenue Capital in March 2026, funding $7.0 million (Tranche 1) and incurring associated debt discounts and derivative liabilities.
- Liquidity: Cash balances more than doubled to $10.3 million, supported by the new debt facility and the collection of a $1.1 million stock subscription receivable.
Outlook, Risks, and Management Commentary
- Clinical Progress: An interim analysis of the GX-03 Phase 2 trial for AD was completed in June 2026 with 50 patients. The trial has been expanded to enroll an additional 120-135 patients across the full EASI spectrum, with enrollment expected to complete in Q4 2026. No major safety concerns were noted.
- Capital Requirements: Management estimates a need for approximately $60-$65 million to complete planned Phase 3 trials for AD and onychomycosis, plus $2.5 million for a Phase 2a study in Hidradenitis Suppurativa (HS).
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern. While current cash is projected to fund operations into Q3 2027, capital resources may not be sufficient for the next 12 months without additional financing.
- Financing Strategy: Future funding is expected to come from equity offerings, draw-downs under the GEM Share Purchase Agreement (up to $85 million aggregate limit), and potential future tranches of the Avenue Capital loan (up to $18 million additional).
Investor Verification Checklist
- Derivative Liability Volatility: Verify the sensitivity of the $6.1 million derivative liability to stock price fluctuations, as this significantly impacts reported net loss.
- Cash Runway: Confirm the specific monthly burn rate and the timeline for the next capital raise given the "substantial doubt" disclosure.
- Debt Covenants: Review the specific milestones required to unlock Tranche 2 ($8 million) and Tranche 3 ($10 million) of the Avenue Capital loan, including the requirement for positive Phase 2 data.
- Clinical Trial Expansion: Monitor the enrollment progress and interim data readout for the expanded GX-03 AD trial scheduled for Q4 2026.
- Deferred Offering Costs: Track the amortization schedule of the $5.6 million deferred offering cost, which will continue to impact non-cash expenses.